-
RNA in Oncology Research, Ultima Genomics Commercially Launches Platform, More
Bio-IT World| InfoBionic.Ai’s MoMe ARC delivers real-time cardiac insights, empowering physicians to improve patient outcomes; Ultima Genomics announced the commercial launch of UG 100 Solaris; and more.
Feb 27, 2025
-
Follow the Money: 3D Spatial Biology, AI-Powered Imaging Biomarkers, More
Bio-IT World| Stellaromics commercializes their 3D spatial biology platform, Pyxa; Latent Labs’ AI platform shows promising potential to open new paths to personalized medicines; and more.
Feb 26, 2025
-
Eli Lilly’s CISO Andrea Abell on Safeguarding Innovation in Pharma
Bio-IT World| Earlier this week at the ViVE conference in Nashville, Tenn., Bio-IT World editor, Allison Proffitt, sat down with Andrea Abell, Eli Lilly’s Chief Information Security Officer (CISO), whose mission is to protect the integrity of pharmaceutical research from inception to patient delivery. Together they discussed the critical role cybersecurity plays in Lilly’s broader goal of bringing life-changing medicines to market.
Feb 20, 2025
-
Illumina’s New Spatial Products
Bio-IT World| Today, Illumina announced a new spatial technology program of Illumina sequencers and a multimodal analysis platform. The company also announced a collaboration with the Broad Institute on spatial transcriptomics. Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.
Feb 19, 2025
-
AI in Healthcare: How To Assess What Works
Bio-IT World| At a panel discussion this week at the ViVE conference in Nashville, Tenn., researchers and physicians discussed the promise and hype of AI. Moderated by Alexander Morgan, partner at Khosla Ventures, the discussion was wide ranging and discussed the AI tools ready for use by physicians; which classes of AI are not yet delivering; and how to assess what’s right for you.
Feb 18, 2025
-
Ultima Genomics Sequencing Platform Selected for UK Biobank Study
Bio-IT World| Last month, Ultima Genomics announced that their UG 100 sequencing platform was selected by UK Biobank to be used in their human proteomics study, which is anticipated to be the largest and most comprehensive proteomics study to date. The study is intended to quantify more than 5,400 protein markers across 600,000 samples, which will help researchers understand how protein levels fluctuate over time and how these changes correlate with disease progression and aging.
Feb 14, 2025


